Doi.org/10.1177/1078155218755548
Jump to navigation
Jump to search
Target Article[edit | edit source]
Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer - real world claim data ; Henry W C Leung Agnes L F Chan Shyh Yau Wang; NULL; 01/01/2018; https://doi.org/10.1177/1078155218755548
Reasons[edit | edit source]
Note: Reasons not yet here included, but you are welcome to insert this information whenever you wish.